Low urgency

Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments

Detected July 30, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

DEA updates Form 222 to a new single-sheet format for ordering Schedule I and II controlled substances; technical amendments effective April 20, 2026.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. All DEA registrants who order Schedule I or II controlled substances using DEA Form 222. should confirm how it applies to their specific situation before acting. There is a time constraint attached: April 20, 2026 (effective date of the rule).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

DEA Form 222 is now a single-sheet format instead of the previous multi-part form; technical amendments to the regulations.

Who it affects

All DEA registrants who order Schedule I or II controlled substances using DEA Form 222.

What you must do

Use the new single-sheet Form 222 for all orders of Schedule I and II controlled substances after the effective date.

Deadline

April 20, 2026 (effective date of the rule).

Source: https://www.federalregister.gov/documents/2026/03/20/2026-05482/ordering-schedule-i-and-ii-controlled-substances-using-dea-form-222-technical-amendments

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)